<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): January 12, 2009</B>

<P style="font-size: 24pt" align="center"><B>IMMTECH PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>001-14907</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>39-1523370</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>One North End Avenue<BR>
New
York, New York <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>10282</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(212) 791-2911</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM 1.01 Entry into a Material
Definitive Agreement</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">On January&nbsp;12,
2009, Immtech Hong Kong Limited (&#8220;Immtech HK&#8221;) and Super Insight
Limited (&#8220;Super Insight&#8221;) (collectively, the
&#8220;Vendors&#8221;), Immtech Life Science Limited (&#8220;Immtech
Life&#8221;) and Chen Jian Yuan (the &#8220;Purchaser&#8221;) entered into a
Sale and Purchase Agreement (the &#8220;Agreement&#8221;), pursuant to which
the Purchaser purchased all of the issued share capital of Immtech Life, a
subsidiary wholly owned indirectly by Immtech Pharmaceuticals, Inc. (the
&#8220;Company&#8221;).

<P style="font-size: 10pt; text-indent: 7%" align="left">Under the terms of the
Agreement, (i)&nbsp;the Vendors have agreed to sell and Purchaser has agreed to
purchase 100 issued ordinary shares of Immtech Life (the &#8220;Sale
Shares&#8221;) and (ii)&nbsp;Super Insight has agreed to assign the
shareholder&#8217;s loan due from Immtech Life to Super Insight (the
&#8220;Shareholder&#8217;s Loan&#8221;) to the Purchaser. The total
consideration for the Sale Shares and the Shareholder&#8217;s Loan is
$2,000,000. The Vendors received the initial payment of $600,000 on
January&nbsp;12, 2009. The remaining $1,400,000 will be paid on or before
March&nbsp;19, 2009.

<P style="font-size: 10pt" align="left"><B>ITEM 2.01 Completion of Acquisition
or Disposition of Assets.</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">On January&nbsp;12,
2009, the Company sold all of the issued share capital of Immtech Life, a
subsidiary wholly owned indirectly by the Company, to the Purchaser pursuant to
the Agreement. The assets of Immtech Life consisted solely of two floors of a
building and the land use rights to such property in the Futian Free Trade Zone
in Shenzhen, People&#8217;s Republic of China.

<P style="font-size: 10pt; text-indent: 7%" align="left">The total
consideration for the Sale Shares and the Shareholder&#8217;s Loan is
$2,000,000. The Vendors received the initial payment of $600,000 on
January&nbsp;12, 2009. The remaining $1,400,000 will be paid on or before
March&nbsp;19, 2009.

<P style="font-size: 10pt" align="left"><B>ITEM 9.01 Financial Statements and
Exhibits.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp;Exhibits

<P style="font-size: 10pt" align="left">The following exhibits are filed
herewith:
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="6%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="91%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>No.</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Exhibit</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Sale and Purchase Agreement, dated
January&nbsp;12, 2009, among Super Insight Limited, Immtech Hong Kong Limited,
Chen Jian Yuan, and Immtech Life Science Limited.</TD>
 </TR>

<tr><td>&nbsp;</td></tr>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.2 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated January&nbsp;16, 2009,
announcing the sale of Sale Shares of Immtech Life Science Limited.</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 7%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.

<P style="font-size: 10pt" align="left">Date: January&nbsp;16, 2009

<P style="margin-top: -11pt; font-size: 10pt; margin-left: 46%"
align="left"><B>IMMTECH PHARMACEUTICALS, INC.</B>

<P style="font-size: 10pt; margin-left: 46%" align="left"><U>/s/ Eric L.
Sorkin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Eric L. Sorkin<BR>
Chairman, Chief Executive Officer and
President<BR>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><U><B>EXHIBIT INDEX</B></U>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="6%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="91%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>No.</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Exhibit</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Sale and Purchase Agreement, dated
January&nbsp;12, 2009, among Super Insight Limited, Immtech Hong Kong Limited,
Chen Jian Yuan, and Immtech Life Science Limited.</TD>
 </TR>
<tr><td>&nbsp;</td></tr>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.2 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated January&nbsp;16, 2009,
announcing the sale of Sale Shares of Immtech Life Science Limited.</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c79456e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 10778}]
{"company-data": {"conformed-name": "IMMTECH PHARMACEUTICALS, INC.", "cik": "0000882509", "assigned-sic": "2836", "irs-number": "391523370", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14907", "film-number": "09532264"}, "business-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061", "phone": "(847) 573-0033"}, "mail-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061"}, "former-company": {"former-conformed-name": "IMMTECH INTERNATIONAL INC", "date-changed": "19980824"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): January 12, 2009
IMMTECH PHARMACEUTICALS,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
001-14907
39-1523370
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One North End Avenue
New
York, New York
10282
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(212) 791-2911
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01 Entry into a Material
Definitive Agreement
On January 12,
2009, Immtech Hong Kong Limited ("Immtech HK") and Super Insight
Limited ("Super Insight") (collectively, the
"Vendors"), Immtech Life Science Limited ("Immtech
Life") and Chen Jian Yuan (the "Purchaser") entered into a
Sale and Purchase Agreement (the "Agreement"), pursuant to which
the Purchaser purchased all of the issued share capital of Immtech Life, a
subsidiary wholly owned indirectly by Immtech Pharmaceuticals, Inc. (the
"Company").
Under the terms of the
Agreement, (i) the Vendors have agreed to sell and Purchaser has agreed to
purchase 100 issued ordinary shares of Immtech Life (the "Sale
Shares") and (ii) Super Insight has agreed to assign the
shareholder's loan due from Immtech Life to Super Insight (the
"Shareholder's Loan") to the Purchaser. The total
consideration for the Sale Shares and the Shareholder's Loan is
$2,000,000. The Vendors received the initial payment of $600,000 on
January 12, 2009. The remaining $1,400,000 will be paid on or before
March 19, 2009.
ITEM 2.01 Completion of Acquisition
or Disposition of Assets.
On January 12,
2009, the Company sold all of the issued share capital of Immtech Life, a
subsidiary wholly owned indirectly by the Company, to the Purchaser pursuant to
the Agreement. The assets of Immtech Life consisted solely of two floors of a
building and the land use rights to such property in the Futian Free Trade Zone
in Shenzhen, People's Republic of China.
The total
consideration for the Sale Shares and the Shareholder's Loan is
$2,000,000. The Vendors received the initial payment of $600,000 on
January 12, 2009. The remaining $1,400,000 will be paid on or before
March 19, 2009.
ITEM 9.01 Financial Statements and
Exhibits.
(d) Exhibits
The following exhibits are filed
herewith:
No.
Exhibit
99.1
Sale and Purchase Agreement, dated
January 12, 2009, among Super Insight Limited, Immtech Hong Kong Limited,
Chen Jian Yuan, and Immtech Life Science Limited.
99.2
Press release, dated January 16, 2009,
announcing the sale of Sale Shares of Immtech Life Science Limited.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: January 16, 2009
IMMTECH PHARMACEUTICALS, INC.
/s/ Eric L.
Sorkin
Eric L. Sorkin
Chairman, Chief Executive Officer and
President
EXHIBIT INDEX
No.
Exhibit
99.1
Sale and Purchase Agreement, dated
January 12, 2009, among Super Insight Limited, Immtech Hong Kong Limited,
Chen Jian Yuan, and Immtech Life Science Limited.
99.2
Press release, dated January 16, 2009,
announcing the sale of Sale Shares of Immtech Life Science Limited.